Loading clinical trials...
Loading clinical trials...
The majority of patients with moderate to severe chronic kidney disease (CKD) (stages 3 and 4) develop secondary hyperparathyroidism (2°HPT), but the optimal therapy to control hyperparathyroidism in ...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Indiana University School of Medicine
NCT03716128 · Renal Osteodystrophy
NCT03960437 · Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy, and more
NCT02556216 · Renal Osteodystrophy
NCT00859612 · Renal Osteodystrophy
NCT00364234 · Renal Osteodystrophy
Indiana University School of Medicine
Indianapolis, Indiana
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions